B. Li

ORCID: 0000-0003-4002-5723
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Research Studies
  • Colorectal and Anal Carcinomas
  • Neuroendocrine Tumor Research Advances
  • Salivary Gland Tumors Diagnosis and Treatment
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Viral-associated cancers and disorders
  • Lymphadenopathy Diagnosis and Analysis
  • Gastrointestinal disorders and treatments
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • IgG4-Related and Inflammatory Diseases
  • Cancer Genomics and Diagnostics
  • Hydrocarbon exploration and reservoir analysis
  • Cutaneous lymphoproliferative disorders research
  • Gallbladder and Bile Duct Disorders
  • Gastrointestinal Tumor Research and Treatment
  • PI3K/AKT/mTOR signaling in cancer
  • Cancer, Lipids, and Metabolism
  • Pancreatic and Hepatic Oncology Research
  • Ferroptosis and cancer prognosis
  • Phytochemical compounds biological activities
  • Medical Imaging and Pathology Studies
  • CNS Lymphoma Diagnosis and Treatment
  • Inflammatory Myopathies and Dermatomyositis
  • Bladder and Urothelial Cancer Treatments
  • Geological formations and processes

Soochow University
2025

Soochow University
2025

Fudan University Shanghai Cancer Center
2024-2025

Shanghai Medical College of Fudan University
2024-2025

Fudan University
2015-2024

Wuhan University
2024

Renmin Hospital of Wuhan University
2024

National Institute for Occupational Health and Poison Control
2024

Chinese Center For Disease Control and Prevention
2024

ProQuest (United States)
2023

EIF5A2, eukaryotic translation initiation factor 5A2, is associated with several human cancers. In this study, we investigated the role of EIF5A2 in metastatic potential localised invasive bladder cancer (BC) and its underlying molecular mechanisms were explored. The expression pattern BC was determined by immunohistochemistry. addition, function elucidated a series vitro vivo assays. Overexpression an independent predictor for poor metastasis-free survival patients treated radical...

10.1038/bjc.2014.52 article EN cc-by-nc-sa British Journal of Cancer 2014-02-06

Long-term exposure to lead (Pb) can result in chronic damage the body through accumulation central nervous system (CNS) leading neurodegenerative diseases, such as Alzheimer’s disease (AD). This study delves into intricate role of miR-671/CDR1as regulation etiology AD-like lesions triggered by Pb adult mice. To emulate effects Pb, we established a rodent model spanning 10 months controlled administration, dividing 52 C57BL/6J mice groups receiving varying concentrations (1, 2, or 4 g/L)...

10.3390/toxics12060410 article EN cc-by Toxics 2024-06-04

Inactivation of p53 by mutations commonly occurs in human cancer. The mutated proteins may escape proteolytic degradation and exhibit high expression tumors acquire gain-of-function activity that promotes tumor progression chemo-resistance. Therefore, selectively targeting the mutants serve as a promising therapeutic strategy for cancer prevention treatment. In this study, we identified cabozantinib, multikinase inhibitor currently used clinical treatment several types cancer, selective...

10.1016/j.jbc.2025.108167 article EN cc-by Journal of Biological Chemistry 2025-01-08

Background: Ferroptosis plays a vital role in cancer development and treatment. The relationship between ferroptosis-related genes breast prognosis, as well immunotherapy outcomes, remains unknown. Objectives: To evaluate the prognostic value of cancer. Methods: We conducted differential expressions analysis for on public databases patients our center analyzed their predictive patients. Results: identified genes, constructed nomogram, validated key using patient data from center. also...

10.1177/17588359251322291 article EN cc-by-nc Therapeutic Advances in Medical Oncology 2025-01-01

The aim of this study was to assess the correlation sperm morphology with intrauterine insemination (IUI) outcome in patients normal concentration and motility. About 412 couples who underwent 908 IUI cycles were involved present study. A total 110 clinical pregnancies achieved a pregnancy rate 12.11% per cycle. rates cycle 7.60%, 12.67%, 13.62% 13.13% <5%, 5-9%, 10-14% >14% forms, respectively. lowest (7.60%) obtained group forms below 5%. However, not significantly different from other...

10.1111/j.1439-0272.2012.01280.x article EN Andrologia 2012-02-16

10.1016/j.remnie.2016.04.005 article EN Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2016-06-18

10.1016/j.remn.2017.04.006 article ES Revista Española de Medicina Nuclear e Imagen Molecular 2017-06-10

10.1016/j.remnie.2017.10.027 article ES Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2018-05-01

10.1016/j.remnie.2015.12.016 article EN Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2016-08-11

This prospective, two-cohort phase 2 trial with random allocation was conducted to evaluate the safety and efficacy of neoadjuvant tislelizumab combined nab-paclitaxel/paclitaxel cisplatin (TP) in patients esophageal squamous cell carcinoma (ESCC). Patients were enrolled randomly assigned nab-paclitaxel or paclitaxel cohorts at a 1:1 ratio, received intravenous (200 mg, day 1) (25 mg/m

10.1002/ijc.35261 article EN International Journal of Cancer 2024-12-16

10.1016/j.remn.2015.11.002 article EN Revista Española de Medicina Nuclear e Imagen Molecular 2015-12-31

10.1016/j.remn.2015.06.001 article EN Revista Española de Medicina Nuclear e Imagen Molecular 2015-08-29

Abstract Background Obesity paradox in heart failure (HF) is defined as better outcomes associated with higher body mass index (BMI). Purpose We explored the relationship between BMI and cardiogenic shock (CS) due to acute myocardial infarction. Methods The Cardiogenic Shock Working Group (CSWG) registry includes patients CS, regardless of etiology, from 17 clinical sites across USA. In- hospital mortality, a main outcome measure, was analyzed depending on continuous variable, well quartiles...

10.1093/eurheartj/ehad655.1144 article EN European Heart Journal 2023-11-01

10.1016/j.remn.2016.06.009 article EN Revista Española de Medicina Nuclear e Imagen Molecular 2016-11-09

10.1016/j.remn.2015.12.006 article EN Revista Española de Medicina Nuclear e Imagen Molecular 2016-03-29

10.1016/j.remnie.2015.12.006 article EN Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2015-12-29

10.1016/j.remnie.2020.09.008 article EN Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2020-09-26

10.1016/j.remn.2021.03.005 article ES Revista Española de Medicina Nuclear e Imagen Molecular 2022-03-16
Coming Soon ...